ADPT: Adaptive Biotech Price to Sales
Complex climate-controlled transportation of biosamples increases operating expenses, which is reflected in the calculated P/S. The value of 16.00 determines the latest valuation metric. Robotic conveyors for 24/7 DNA sequencing and unique AI data analysis algorithms serve as the solution. An extensive archive of immune receptors creates a barrier for third-party players, cementing the leadership of Adaptive Biotechnologies (ADPT) in high-tech mapping.
Metric breakdowns and analytics for Adaptive Biotechnologies Corp (ADPT)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Adaptive Biotechnologies|ADPT - Long-Term Debt to Equity|Current Liabilities to Equity Adaptive Biotechnologies Inc.|ADPT - Company Total Debt|Debt to Book Capital Adaptive Biotechnologies Corp|ADPT - Company Long-Term Debts|Short-Term Debt Volume Adaptive Biotechnologies|Quick Liquidity adaptivebiotech.com
- company profitability and valuation multiples indicators:
ADPT - Net Profit|Expected Net Profit Adaptive Biotechnologies|ADPT - Price to Earnings Ratio|Future Price to Earnings Multiple Adaptive Biotech|ADPT - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies Corp|ADPT - Operating profit EBITDA|Net earnings per share for the last four quarters Adaptive Biotechnologies|ADPT - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months adaptivebiotech.com|ADPT - Net earnings per share growth this year|Projected earnings per share increase next year Adaptive Biotechnologies
- issuer revenue and sales details:
Summary company analytics:adaptivebiotech.com
The P/S ratio determines the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of generated income. Optimized biosample logistics at Adaptive Biotechnologies (ADPT) ensure a steady flow of research, making the current price-to-sales ratio a key indicator of the asset's fundamental value amid interest rate volatility.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|IMVT: P/S Multiple|Market Cap to Revenue Ratio KNSA|GRFS (Grifols) - P/S Multiple|P/S Multiple Celldex Therapeutics Inc|Price-to-Revenue Ratio Aurinia Pharma (AUPH)|BCRX: Price-to-Sales Ratio|Vera Therapeutics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume DNTH (dianthustx.com)|Pharvaris - P/S Multiple|Price-to-Revenue Coefficient AbCellera Biologics Inc. ABCL|TRML (Tourmaline Corp) - Market Cap to Revenue|PGEN (Precigen Corp) - Price-to-Revenue Ratio|PHAR (Pharming Group N.V.) - P/S Multiple|Price to Sales nektar.com NKTR|Market Cap to Revenue UPB (Upstream Bio)|ZBIO (Zenas Bio) - Market Capitalization-to-Revenue Ratio|P/S Multiple IMNM (Immunome Corp)|Gossamer Bio Corp. - Price-to-Revenue Ratio|KalVista Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient septerna.com SEPN|Pieris Pharmaceuticals, Inc. (PVLA) - Price-to-Revenue Ratio|Price to Sales Savara Inc (SVRA)|Market Cap to Revenue RIGL|ANAB (AnaptysBio Inc.) - Market Cap to Sales Volume|P/S Multiple ATXS|ENGN - Price to Sales|P/S Multiple RAPT (RAPT Therapeutics)|JBIO - Market Cap to Revenue|Aclaris - P/S Multiple|Market Capitalization-to-Revenue Ratio KYTX (Kyverna Therapeutics, Inc)|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CABA|Price-to-Revenue Ratio Ventyx Biosciences, Inc.|Price to Sales Theratechnologies, Inc. THTX|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|Price-to-Revenue Ratio ELDN (Eledon Pharmaceuticals, Inc)|Price-to-Revenue Ratio Agenus AGEN|climbbio.com (CLYM) - Price to Sales|Zura Bio - P/S Multiple|Price-to-Revenue Multiple aTyr Pharma Inc (ATYR)|ADAG: P/S Multiple|IMA - Price-to-Revenue Coefficient|STTK (Shattuck Labs Inc) - P/S Multiple|Price to Sales Equillium Bio EQ|Price-to-Revenue Ratio Connect Biopharma (CNTB)|Price-to-Revenue Coefficient immunic-therapeutics.com|P/S Multiple ATRA (Atara Bio)|P/S Multiple InflaRx NV IFRX|X4 Pharmaceuticals - P/S Multiple|ACET (Adicet Bio) - Market Cap to Revenue Ratio|celularity.com (CELU) - Price-to-Revenue Ratio|Price-to-Sales Ratio INMB (INmune Bio Inc)|Market Cap to Revenue BRNS|KZR (Kezar Life Sciences Inc) - Market Cap to Sales Volume|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|AKTX: Price-to-Sales Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Market Capitalization-to-Revenue Ratio QTTB|GeoVax Labs Inc - P/S Multiple|EDSA - P/S Multiple|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Carisma Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|P/S Multiple HCWB|P/S Multiple aptevotherapeutics.com (APVO)|AIM ImmunoTech Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio - P/S Multiple|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Revelation Biosciences Corp|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue scinai.com (SCNI)|Market Cap to Revenue CALI (CalciMedica, Inc.)|P/S Multiple affimed.com (AFMD)|Price-to-Revenue Ratio Allakos ALLK|HOOK: Market Cap to Revenue Ratio|IGM Bio - P/S Multiple|Price to Sales iteostherapeutics.com|OCEA: P/S Multiple|TC BioPharm (Holdings) Plc (TCBP) - P/S Multiple|THRD (Third Harmonic Bio, Inc) - P/S Multiple
